Session » B Cell Biology and Targets in Autoimmune Disease Poster

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 41

A Fine Bioinformatical Analysis of Lymphocyte Distribution Predicts the Diagnosis of Systemic Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 25

A Novel Role for Galectin-3 Binding Protein in B Cell Biology and Antibody Secretion

9:00AM-11:00AM: Abstract Number: 23

Auto-Reactive B Cells Escape Peripheral Tolerance Checkpoints in Patients with PR3-ANCA Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 33

B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 40

B-Cell Attracting Chemokine-1 (BCA-1) and Macrophage Inflammatory Protein-3 Alpha (MIP-3α) Act Synergistically in the Recruitment of B Cells in the Rheumatoid Synovium

9:00AM-11:00AM: Abstract Number: 35

B-Cell Subset Differences in Inflammatory Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 45

BIIB063, a Potent Anti-CD40 Antagonistic Monoclonal Antibody (MAb): Lessons Learned from an Early Development Program.

9:00AM-11:00AM: Abstract Number: 22

Bone Regulatory Cytokine Production By B Cells in Rheumatoid Arthritis Is Dependent on NF-κb Activation and Autophagy Pathways

9:00AM-11:00AM: Abstract Number: 29

BTK Inhibition Ameliorates Lupus-Associated Neuropsychiatric and Skin Disease

9:00AM-11:00AM: Abstract Number: 44

Characterization of Novel Stromal-Derived Autoantigens Recognized By RA Synovial Monoclonal Antibodies

9:00AM-11:00AM: Abstract Number: 38

Cytokine Production By CpG-Activated B Cells Require Glutaminolysis to Drive mTOR Activation, Aerobic Glycolysis and Mitochondrial Respiration

9:00AM-11:00AM: Abstract Number: 27

Effects of High Titers of Anti-Chimeric Antibodies Following Rituximab

9:00AM-11:00AM: Abstract Number: 36

GM-CSF-Producing B Cells: A Novel B Cell Subset Involved in the Pathogenesis of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 34

IL-23 Regulates Development of Spontaneous Germinal Centers and Pathogenic Autoantibody Production in BXD2 Mice

9:00AM-11:00AM: Abstract Number: 32

Longitudinal Associations between Rheumatoid Factor and Ex Vivo Cytokine Production Reveal Novel Mechanistic Insights into Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 20

Low Molecular Weight BAFF Receptor Antagonists Restrain Infiltration of B Cells into Organs of Autoimmune Model Mice By Suppressing B Cell Activation

9:00AM-11:00AM: Abstract Number: 39

Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment

9:00AM-11:00AM: Abstract Number: 21

Reciprocal Regulation of B Cells on Bleomycin-Induced Scleroderma Model: IL-6-Producing Effector B Cells Play a Pathogenic Role, While IL-10-Producing Regulatory B Cells Play a Protective Role

9:00AM-11:00AM: Abstract Number: 43

Regulation of TLR7 Signalling By UBE2L3 Dependent Linear Ubiquitination Explains Dimethyl Fumarate Suppression of Autoreactive B Cell Development in SLE

9:00AM-11:00AM: Abstract Number: 42

Resveratrol Regulates Sirt1 to Control B Cells Activation and Plasma B Cells Differentiation

9:00AM-11:00AM: Abstract Number: 28

Sapril and Sbcma As Potential Biomarkers of B Cell Hyperactivation in Rheumatoid Arthritis: A Cluster Analysis Approach

9:00AM-11:00AM: Abstract Number: 46

Secondary Light Chain Editing and Allelic Inclusion in Antibody Secreting Cells from the Minor Salivary Gland

9:00AM-11:00AM: Abstract Number: 26

Single B Cell Analysis Revealed the Relationship Among the Cytokine Profile, Antibody Affinity, and Pathogenic Roles of Autoantigen-Reactive B Cells in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 31

Single Cell Analysis Revealed That the Response to Cyclophosphamide Therapy Is Regulated By B Cells in Systemic Sclerosis-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 30

Specificity of Salivary Gland-Derived Monoclonal Antibodies from Sjogren’s Syndrome Patients Using Human Proteome Arrays

9:00AM-11:00AM: Abstract Number: 19

The Transcription Factor Specificity Protein 1 up-Regulates IL-21 Receptor Expression on B Cells in Rheumatoid Arthritis Leading to Altered Cytokine Production and Maturation

9:00AM-11:00AM: Abstract Number: 24

Trafficking of Innate B Cells to the Lungs As a Novel Mechanism in a Model of Pulmonary Lupus and Vasculitis

9:00AM-11:00AM: Abstract Number: 37

β2-Glycoprotein I Binds to Necroptotic Cells and Serves As a Target for SLE Autoantibodies

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].